Bruno Villoutreix

Prof. Bruno Villoutreix

INSERM - Institut National de la Santé et de la Recherche Médicale
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2017 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
DLDavid Lagorce
David Lagorce
LBLina Bouslama
Lina Bouslama
JBJerome Becot
Jerome Becot
Maria A. MitevaMaria A. Miteva
Maria A. Miteva
Bruno VilloutreixBruno Villoutreix
Bruno Villoutreix
Identification of small molecules that could be interesting starting points for drug discovery or to investigate a biological system as in chemical biology endeavours is both time consuming and costly. In silico approaches that assist the design of quality compound collections or help to prioritize molecules before synthesis or purchase are therefore valuable. Here quality refers to the selection of molecules that pass one or several selected filters that can be tuned by the users according to the project and the stage of the project. These filters can involve prediction of physicochemical properties, search for toxicophores or other unwanted chemical groups. FAF-Drugs4 is a novel version of our online server dedicated to the preparation and annotation of compound collections. The tool is now faster and several parameters have been optimized. In addition, a new service referred to as FAF-QED, an implementation of the quantitative estimate of drug-likeness method, is now available. The server is available at http://fafdrugs4.mti.univ-paris-diderot.fr. Supplementary data are available at Bioinformatics online.

1 July 2005 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
BDBjörN DahlbäcK
BjörN DahlbäcK
Bruno VilloutreixBruno Villoutreix
Bruno Villoutreix
The protein C system provides important control of blood coagulation by regulating the activities of factor VIIIa (FVIIIa) and factor Va (FVa), cofactors in the activation of factor X and prothrombin, respectively. The system comprises membrane-bound and circulating proteins that assemble into multi-molecular complexes on cell surfaces. Vitamin K-dependent protein C, the key component of the system, circulates in blood as zymogen to an anticoagulant serine protease. It is efficiently activated on the surface of endothelial cells by thrombin bound to the membrane protein thrombomodulin. The endothelial protein C receptor (EPCR) further stimulates the protein C activation. Activated protein C (APC) together with its cofactor protein S inhibits coagulation by degrading FVIIIa and FVa on the surface of negatively charged phospholipid membranes. Efficient FVIIIa degradation by APC requires not only protein S but also intact FV, which like thrombin is a Janus-faced protein with both procoagulant and anticoagulant potential. In addition to its anticoagulant properties, APC has antiinflammatory and antiapoptotic functions, which are exerted when APC binds to EPCR and proteolytic cleaves protease-activated receptor 1 (PAR-1). The protein C system is physiologically important, and genetic defects affecting the system are the most common risk factors of venous thrombosis. The proteins of the protein C system are composed of multiple domains and the 3-dimensional structures of several of the proteins are known. The molecular recognition of the protein C system is progressively being unraveled, giving us new insights into this fascinating and intricate molecular scenario at the atomic level.

1 January 2012 in Drug Discovery Today
Verified
Journal Article
Closed access
GMGautier Moroy
Gautier Moroy
VMVirginie Y. Martiny
Virginie Y. Martiny
PVPhilippe Vayer
Philippe Vayer
Bruno VilloutreixBruno Villoutreix
Bruno Villoutreix
Maria A. MitevaMaria A. Miteva
Maria A. Miteva

1 August 2010 in Drug Discovery Today
Verified
Journal Article
Closed access
SPStéphanie Pérot
Stéphanie Pérot
OSOlivier Sperandio
Olivier Sperandio
Maria A. MitevaMaria A. Miteva
Maria A. Miteva
ACAnne-Claude Camproux
Anne-Claude Camproux
Bruno VilloutreixBruno Villoutreix
Bruno Villoutreix

8 April 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
CLCéline M. Labbé
Céline M. Labbé
JRJulien Rey
Julien Rey
DLDavid Lagorce
David Lagorce
MVMarek Vavruša
Marek Vavruša
JBJérome Becot
Jérome Becot
Maria A. MitevaMaria A. Miteva
Maria A. Miteva
Open screening endeavors play and will play a key role to facilitate the identification of new bioactive compounds in order to foster innovation and to improve the effectiveness of chemical biology and drug discovery processes. In this line, we developed the new web server MTiOpenScreen dedicated to small molecule docking and virtual screening. It includes two services, MTiAutoDock and MTiOpenScreen, allowing performing docking into a user-defined binding site or blind docking using AutoDock 4.2 and automated virtual screening with AutoDock Vina. MTiOpenScreen provides valuable starting collections for screening, two in-house prepared drug-like chemical libraries containing 150 000 PubChem compounds: the Diverse-lib containing diverse molecules and the iPPI-lib enriched in molecules likely to inhibit protein–protein interactions. In addition, MTiOpenScreen offers users the possibility to screen up to 5000 small molecules selected outside our two libraries. The predicted binding poses and energies of up to 1000 top ranked ligands can be downloaded. In this way, MTiOpenScreen enables researchers to apply virtual screening using different chemical libraries on traditional or more challenging protein targets such as protein–protein interactions. The MTiOpenScreen web server is free and open to all users at http://bioserv.rpbs.univ-paris-diderot.fr/services/MTiOpenScreen/.

24 September 2008 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
DLDavid Lagorce
David Lagorce
OSOlivier Sperandio
Olivier Sperandio
HGHervé Galons
Hervé Galons
Maria A. MitevaMaria A. Miteva
Maria A. Miteva
Bruno VilloutreixBruno Villoutreix
Bruno Villoutreix
Background: Drug discovery and chemical biology are exceedingly complex and demanding enterprises. In recent years there are been increasing awareness about the importance of predicting/optimizing the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of small chemical compounds along the search process rather than at the final stages. Fast methods for evaluating ADMET properties of small molecules often involve applying a set of simple empirical rules (educated guesses) and as such, compound collections' property profiling can be performed in silico. Clearly, these rules cannot assess the full complexity of the human body but can provide valuable information and assist decision-making. Results: This paper presents FAF-Drugs2, a free adaptable tool for ADMET filtering of electronic compound collections. FAF-Drugs2 is a command line utility program (e.g., written in Python) based on the open source chemistry toolkit OpenBabel, which performs various physicochemical calculations, identifies key functional groups, some toxic and unstable molecules/functional groups. In addition to filtered collections, FAF-Drugs2 can provide, via Gnuplot, several distribution diagrams of major physicochemical properties of the screened compound libraries. Conclusion: We have developed FAF-Drugs2 to facilitate compound collection preparation, prior to (or after) experimental screening or virtual screening computations. Users can select to apply various filtering thresholds and add rules as needed for a given project. As it stands, FAF-Drugs2 implements numerous filtering rules (23 physicochemical rules and 204 substructure searching rules) that can be easily tuned.